Altai Protocol Library
Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions
New Reference: Taletrectinib for ROS1-Positive NSCLC
Phase 2, open-label, single-arm, multicenter trials (TRUST-I and TRUST-II) ROS1-positive advanced or metastatic NSCLC Taletrectinib 600 mg once daily
New Protocol: Regorafenib Maintenance for Sarcoma
Double-blind, placebo-controlled, randomized phase 2 trial (EREMISS) Advanced non-adipocytic soft tissue sarcomas post 1st-line doxorubicin-based chemotherapy Regorafenib 120 mg/da
New Indication: Nivolumab – Ipilimumab for Neoadjuvant NSCLC
Phase 3, randomized, open-label trial (CheckMate 816) Stage IB-IIIA resectable NSCLC Neoadjuvant nivolumab + ipilimumab vs. chemotherapy
New Protocol: Eribulin with Trastuzumab-Pertuzumab in First-Line Breast Cancer
Phase 3, randomized, open-label, noninferiority trial (EMERALD) HER2+ locally advanced/metastatic breast cancer Eribulin + trastuzumab + pertuzumab vs. Taxane (docetaxel or paclita
New Protocol: Metronomic Capecitabine with Aromatase Inhibitors in Metastatic Breast Cancer
Randomized, open-label, phase 3 trial (MECCA) HR+/HER2- metastatic breast cancer, treatment-naive in metastatic setting Metronomic capecitabine (500 mg TID continuously) + AI vs. A
New Reference: Botensilimab / Balstilimab for Metastatic Sarcomas
Phase 1, open-label, multicenter study (C-800-01) Patients with relapsed/refractory metastatic sarcomas Botensilimab (1 or 2 mg/kg IV Q6W) + Balstilimab (3 mg/kg IV Q2W) for up to
New Reference: Afatinib for NSCLC with Uncommon EGFR Mutations
Open-label, randomized, multicenter phase 3 trial (ACHILLES/TORG1834) Previously untreated non-squamous NSCLC with sensitizing uncommon EGFR mutations (excluding exon20ins and T790
New Indication: Datopotamab Deruxtecan in NSCLC with Actionable Mutations
Phase II, single-arm, open-label study (TROPION-Lung05) Advanced/metastatic NSCLC with actionable genomic alterations Datopotamab deruxtecan 6mg/kg Q3W
Our Solutions
Articles
Computerized Chemotherapy Order Entry
Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …
Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.